To test this hypothesis, we created anti-BCMA-CAR3 T cells and examined their anti-tumor functionality, comparing them to anti-BCMA-CAR2 T cells targeting MM cell lines. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.